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Systematic analysis of COVID-19 infection and 
symptoms in a systemic lupus erythematosus 
population: correlation with disease 
characteristics, hydroxychloroquine use and 
immunosuppressive treatments
We read with interest the article of Bozzalla Cassione et al about 
COVID-19 incidence in their systemic lupus erythematosus 
(SLE) cohort.1 Their study adds useful epidemiological informa-
tion about COVID-19 risk in SLE.1 They suggest that hydroxy-
choloroquine was not protective, but could not draw definite 
conclusion and open the question to immunosuppressive drugs’ 
influence. We would like to share analysis of our SLE cohort 
(n=225) that can help to answer these questions and determine 
COVID-19 infection risk factors.
Determining COVID-19 incidence is challenging: PCR lacks 
sensitivity, was usually realised only in severely ill patients and 
patients with suggestive benign symptoms could stay at home 
without medical contact. We studied the incidence of COVID-19 
infection, either asserted or suspected, by analysing positive 
nasopharyngeal PCR, hospitalisation or contact with emergency 
department, but also suspected diagnosis in ambulatory medi-
cine. Each patient was called by phone to determine COVID-19 
suggestive symptoms since 4 February 2020, date of the first case 
in our country.
Among our patients, 92.9% were female, with a mean (±SD) 
age of 51.7 (±14.9) years. Most recent biological evaluation 
showed positivity for ds- DNA in 24% (median (min–max) levels: 
139 (12–758) IU/mL). Mean (±SD) number of 1997 American 
College of Rheumatology (ACR), 2019 American College of 
Rheumatology/European League Against Rheumatism (ACR/
EULAR) and Systemic Lupus International Collaborating Clinics 
(SLICC) classification criteria were 4.5 (±1.5), 20.0 (±8.1) and 
5.8 (±2.2), respectively. One hundred and fifty- two (68.1%) 
patients received chronic treatment with hydroxychloroquine, 
while 92 (42.4%) had an immunosuppressive treatment (gluco-
corticoid: 25.3%; other immunosuppressive drug: 31.4%). 
Mean (±SD) glucocorticoid dose was 4.2 (±2.9) mg of meth-
ylprednisolone. Immunosuppressive drugs were ledertrexate 
(n=23, 10.2%), mycophenolate/tacrolimus/everolimus (n=21, 
9.3%), azathioprine (n=25, 11.1%), belimumab (n=5, 2.2%) 
and rituximab (n=3, 1.3%).
In our cohort, a high suspicion of COVID-19 infection was 
not uncommon, but with absence of severity. Infection was 
confirmed or suspected by medical team in 18 (8.0%) patients 
(table 1): 5 (2.2%) had a positive PCR; 7 (3.1%) were admitted 
to emergency department (without hospitalisation) and 2 
(0.9%) were hospitalised (without intensive care unit, while 
1 for the Italian cohort1) with COVID-19 infection suspected 
or confirmed by the medical team; and 14 (6.2%) were highly 
suspected of COVID-19 after a medical appointment in ambu-
latory medicine. COVID-19 suggestive symptoms were listed 
in table 1: in particular, anosmia/ageusia were declared in 
7.6%. The Italian cohort identified a similar rate of positive 
PCR (2.5%), but a lower rate of COVID-19 suspicion (4.8%): 
however, they considered a strict definition with association of 
symptoms and contact with a positive case, while we also declare 
high clinical suspicion in ambulatory medicine.1 Another series 
from New York (NY) estimated the incidence of COVID-19 
infection at 2%, but without systematic patient contact2 and 
could miss paucisymptomatic patients.
Our data supported the ineffectiveness of chronic use of 
hydroxychloroquine to prevent COVID-19 disease and symp-
toms in SLE population, with similar rate of COVID-19 infec-
tion or suspicion (infection or suspicion in 12 out of 152 (7.9%) 
patients treated with hydroxychloroquine, while in 6 out of 
73 (8.2%) for patients without, p=0.93) and suggestive symp-
toms (p=0.97). Patients with hydroxychloroquine were slightly 
younger (49.7±14.5 years vs 55.6±15.1 years, p=0.0054) but 
with no difference in terms of gender, biological evaluation, 
classification criteria, or immunosuppressive and non- rheumatic 
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Table 1 COVID-19 infection, suspicion and symptoms among patients with systemic lupus erythematosus (n=225)
Variable Categories N (Percent) Variable Categories
N 
(Percent)
Dyspnea No 212 (94.2) COVID-19 infection confirmed or suspect by medical team No 207 (92.0)
Yes 13 (5.8) Yes 18 (8.0)
Chest pain No 214 (95.1) Positive nasopharyngeal PCR No 220 (97.8)
Yes 11 (4.9) Yes 5 (2.2)
Rhinorrhea No 200 (88.9) Admission to emergency department (without hospitalization) for COVID-19 symptoms No 218 (96.9)
Yes 25 (11.1) Yes 7 (3.1)
Pharyngeal pain No 205 (91.1) Hospitalization for COVID-19 symptoms No 223 (99.1)
Yes 20 (8.9) Yes 2 (0.9)
Cough No 203 (90.2) Suspicion of COVID-19 in ambulatory medicine No 211 (93.8)
Yes 22 (9.8) Yes 14 (6.2)
Diarrhea No 201 (89.3)
Yes 24 (10.7)
Headache No 191 (84.9) Ageusia No 211 (93.8)
Yes 34 (15.1) Yes 14 (6.2)
Myalgia No 209 (92.9) Anosmia No 211 (93.8)
Yes 16 (7.1) Yes 14 (6.2)
Fever No 214 (95.1) Ageusia or anosmia No 208 (92.4)
Yes 11 (4.9) Yes 17 (7.6)
Vomiting No 220 (97.8) Ageusia and anosmia No 214 (95.1)
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treatment, allowing comparison. A French series of 17 SLE 
patients with COVID-19 infection previously suspected that 
hydroxychloroquine did not prevent severe form of COVID-19.3
The question of immunosuppressive drugs’ influence is 
important because patients could be tempted to stop them. Our 
data are reassuring: patients under immunosuppressive treat-
ment did not present a higher rate of COVID-19 infection or 
symptoms (immunosuppressive drug with or without glucocorti-
coids, with glucocorticoids or without glucocorticoids: p=0.38, 
p=0.77 and p=0.21, respectively, for infection; p=0.66, 
p=0.22 and p=0.14, respectively, for symptoms). If each drug 
was analysed separately, a correlation was found between belim-
umab and hospitalisation (p=0.04) but only two patients (0.9%) 
were hospitalised and it was probably without any clinical signif-
icance. Classification between ‘glucocorticoid use’ or ‘not’ did 
not reveal any difference in infection (p=0.42) and suggestive 
symptoms (p=0.89). However, glucocorticoid dose was posi-
tively associated with positive PCR (OR 1.57, p=0.025), hospi-
talisation (OR 4.39, p=0.030), anosmia and ageusia (OR 1.57, 
p=0.025) and diarrhoea (OR 1.75, p=0.018). This should lead 
to caution in patients with higher doses of glucocorticoids. 
Concerns about glucocorticoid chronic use and COVID-19 
have emerged: glucocorticoids were associated with prolonged 
SARS- CoV-2 RNA shedding4 and were risk factors for hospital-
isation in two cohorts of 86 COVID-19- positive patients with 
inflammatory disease5 and 600 COVID-19- positive patients with 
rheumatic disease.6 Of interest, the patient with SLE described 
by Bozzalla Cassione et al and that needed intensive care unit was 
under oral prednisolone 7.5 mg/day.1 Other immunosuppressive 
treatments were not associated with hospitalisation among the 
18 SLE patients with COVID-19 in the NY series.2
Characterisation was performed with analysis of classification 
criteria (positivity and number of criteria), antinuclear antibody 
(ANA) and ds- DNA levels on the most recent blood analysis 
available: none had significant influence, underlying that more 
severe or more active patients with SLE were not at higher 
risk. Of note, age, gender and comorbidities (reflected by ‘non- 
rheumatic’ treatments) did not have major influence.
In addition to the important epidemiological information 
provided by Bozzalla Cassione et al,1 we underlined that a high 
suspicion of COVID-19 infection was not uncommon in our 
cohort, but with absence of severity. Hydroxychloroquine was 
ineffective in prevention. There was no correlation with immu-
nosuppressive drugs except for glucocorticoid dose. Disease 
characteristics were not associated with COVID-19, while 
comorbidities’ influence seemed limited.
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